---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005503"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T16:55:38.587497+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q4 net loss $137.4M; FDA rejects omecamtiv mecarbil NDA

## Summary
- Net loss Q4 2022 $137.4M ($1.45/share) vs $30.6M ($0.36/share) in Q4 2021; full year loss $389.0M ($4.33/share).
- FDA issued Complete Response Letter for omecamtiv mecarbil NDA, citing insufficient evidence from GALACTIC-HF.
- Cash, cash equivalents and investments $829.3M at Dec 31, 2022; 2023 guidance: revenue up to $5M, operating expenses $420-450M.
- SEQUOIA-HCM (aficamten) enrollment complete in Q2 2023 with results expected Q4 2023; second interim analysis of COURAGE-ALS in Q2 2023.
- R&D expenses $75.0M in Q4 2022, up from $43.5M in Q4 2021; G&A $54.0M vs $33.8M.

## SEC filing metadata
- accession: 0000950170-23-005503
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/0000950170-23-005503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/cytk-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005503
- JSON: https://secwatch.observer/filing/0000950170-23-005503.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005503.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported the fourth quarter and full year 2022 results: net income Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 mill.
  - Period: the fourth quarter and full year 2022
  - Net income: Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 mill
  - Result: reported results
  source text: On March 1, 2023, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/0000950170-23-005503-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.